Exact Sciences's revenue per share for the
three
months ended in Dec. 2023 was $3.57.
Exact Sciences's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was $13.81.
During the past 12 months, the average Revenue Per Share Growth Rate of Exact Sciences was 17.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 12.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 26.90% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 84.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Exact Sciences's Revenue per Share or its related term are showing as below:
EXAS'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -34.7 Med: 30.75 Max: 371
Current: 12
During the past 13 years, Exact Sciences's highest 3-Year average Revenue Per Share Growth Rate was 371.00% per year. The lowest was -34.70% per year. And the median was 30.75% per year.
EXAS's 3-Year Revenue Growth Rate is ranked better than 63.37% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 8.6
vs EXAS: 12.00
Exact Sciences Revenue per Share Historical Data
The historical data trend for Exact Sciences's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's Revenue per Share
For the Diagnostics & Research subindustry, Exact Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's PS Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Exact Sciences's PS Ratio falls into.
Exact Sciences Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Exact Sciences's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences (NAS:EXAS) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Exact Sciences Revenue per Share Related Terms
Thank you for viewing the detailed overview of Exact Sciences's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences (Exact Sciences) Business Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 